Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for F...(ge in fair value of invest...),Health

Date:8/18/2009

ge in fair value of investment securities (3,453) (3,453) - Post-retirement liability adjustments, net of $229 tax - - (425) (425) - Adjustment to adopt FIN 48 - - - - (5,934) Issuance of common stock under: Stock options 2,393 32,210 - - - Restricted stock plan 19 - - - - Compensation for stock options - 2,730 - - - Compensation for restricted stock - 5,739 - - - Cash dividends, $0.195 per share - - - - (18,219) Tax effect from stock transactions - 6,603 - - - Purchases and retirements of common stock (2,496) (78,164) - - - ------ ------- ----- ----- ----- Balance at June 28, 2008 93,311 488,537 155,184 234,281 289,994 ======= Net income - - - 144,049 144,049 Accumulated other comprehensive income (loss): Change in fair value of derivative financial instruments, net of $162 tax - - 300 300 - Foreign currency translation adjustments - - (103,450) (103,450) - Change in fair value of investment securities 3,956 3,956 -
'/>"/>

SOURCE Perrigo Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend